Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
NCT00273936 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2011-08-04
Summary
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
Conditions
- Acute Leukemia
- Chronic Leukemia
- Multiple Myeloma
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Waldenstrom's Macroglobulinemia
Interventions
- DRUG
-
AVN-944 capsules for oral administration
Sponsors & Collaborators
-
Vertex Pharmaceuticals Incorporated
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-01-31
Countries
- United States
Study Locations
More Related Trials
-
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
NCT04277442 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
NCT03417154 ·Status: COMPLETED ·Phase: PHASE2
-
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01369849 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
NCT00384228 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia
NCT05941585 ·Status: COMPLETED ·Phase: NA
-
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT05086315 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCT00098488 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
NCT00621244 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
NCT00100152 ·Status: TERMINATED ·Phase: PHASE1
-
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
NCT00449761 ·Status: TERMINATED ·Phase: PHASE2
-
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
NCT00346632 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
NCT04198415 ·Status: COMPLETED
-
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00079378 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03441555 ·Status: COMPLETED ·Phase: PHASE1
-
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02509546 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
NCT00098423 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
NCT00460421 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
NCT04872478 ·Status: RECRUITING ·Phase: PHASE1
-
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
NCT05342584 ·Status: RECRUITING ·Phase: PHASE1
-
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01253447 ·Status: COMPLETED ·Phase: PHASE2
-
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT03571321 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
NCT03797261 ·Status: TERMINATED ·Phase: PHASE1